Blueprint Medicines (BPMC) Misses Q2 EPS by 7c
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.86), $0.07 worse than the analyst estimate of ($0.79).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.86), $0.07 worse than the analyst estimate of ($0.79).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.